pemigatinib (Pemazyre) Report issue

Small molecule Orphan Drug FDA Approved FDA Breakthrough Therapy FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$908.9450 - $1195.9800
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (24)

Research & Development (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (1)


 

Bile Duct Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cholangiocarcinoma (Phase 3)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 2)

Mutation (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2)

Receptors, Fibroblast Growth Factor (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 28
  • # of Trial Organizations: 24

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue